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A reply to the Department of HealthIt is quite a pleasure to know that the Bureau of Medical
Affairs at the Department of Health (DOH) has taken notice
of the article “The Biobank Act as a route to responsible
research: a first step for Taiwan?”1 published in 2011. The
comments from the DOH seek to clarify what the new law
says, and while I do not have any significant disagreements
on the merits of the DOH’s comments, I do have some short
responses, which are as follows.
First of all, my article was officially accepted by this
Journal in early January of 2011, when the interpretation
and application of Articles 29 and 30 of the Biobank Act
were still in a very confusing situation and when it was
quite unclear whether the Legislative Yuan would be willing
to take any action in amending the Act. It seems to me that
the fact the Legislative Yuan has decided to amend Articles
29 and 30 of the Act proves that my analysis on the earlier
versions of Article 29 and 30 was quite correct. In general,
the DOH comment offers a correct reading of the newly
amended Article 29. In other words, it is true that under the
new law, Articles 6, 15, 16, and 20 shall apply, where
appropriate, to those biomedical researches not using
biological specimens, derivatives, relevant data, and
information from the biobanks. However, for those genetic
analyses that are now allowed to be exported with the DOH
approvals, it seems predictable that the biggest challenge
lies in what criteria the DOH will adopt for issuing these0929-6646/$ - see front matter Copyright ª 2012, Elsevier Taiwan LLC
doi:10.1016/j.jfma.2011.06.003approvals, and, while doing so, what kind of legally binding
conditions the DOH shall attach to every specific approval
to ensure the genetic analysis conducted in foreign coun-
tries is done in an ethically acceptable way.
Secondly, the DOH comment mentions that the correc-
tive process has been postponed until February 2012 in the
amended Article 30. In my view, this is a very minor change
of the law and only a matter of time. My earlier observation
that medical research institutions in Taiwan shall figure out
a sensible model as soon as possible to handle the burden
imposed by the Act in maintaining and overseeing their pre-
existing biobanks is still valid.
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